Medizinische Universität Graz Austria/Österreich - Forschungsportal - Medical University of Graz
Gewählte Publikation:
SHR Neuro Krebs Kardio Lipid Stoffw Microb
Kovacs, G; Herve, P; Barbera, JA; Chaouat, A; Chemla, D; Condliffe, R; Garcia, G; Grünig, E; Howard, L; Humbert, M; Lau, E; Laveneziana, P; Lewis, GD; Naeije, R; Peacock, A; Rosenkranz, S; Saggar, R; Ulrich, S; Vizza, D; Vonk Noordegraaf, A; Olschewski, H.
An official European Respiratory Society statement: pulmonary haemodynamics during exercise.
Eur Respir J. 2017; 50(5):
Doi: 10.1183/13993003.00578-2017
[OPEN ACCESS]
Web of Science
PubMed
FullText
FullText_MUG
- Führende Autor*innen der Med Uni Graz
- Kovacs Gabor
- Co-Autor*innen der Med Uni Graz
- Olschewski Horst
- Altmetrics:
- Dimensions Citations:
- Plum Analytics:
- Scite (citation analytics):
- Abstract:
- There is growing recognition of the clinical importance of pulmonary haemodynamics during exercise, but several questions remain to be elucidated. The goal of this statement is to assess the scientific evidence in this field in order to provide a basis for future recommendations.Right heart catheterisation is the gold standard method to assess pulmonary haemodynamics at rest and during exercise. Exercise echocardiography and cardiopulmonary exercise testing represent non-invasive tools with evolving clinical applications. The term "exercise pulmonary hypertension" may be the most adequate to describe an abnormal pulmonary haemodynamic response characterised by an excessive pulmonary arterial pressure (PAP) increase in relation to flow during exercise. Exercise pulmonary hypertension may be defined as the presence of resting mean PAP <25 mmHg and mean PAP >30 mmHg during exercise with total pulmonary resistance >3 Wood units. Exercise pulmonary hypertension represents the haemodynamic appearance of early pulmonary vascular disease, left heart disease, lung disease or a combination of these conditions. Exercise pulmonary hypertension is associated with the presence of a modest elevation of resting mean PAP and requires clinical follow-up, particularly if risk factors for pulmonary hypertension are present. There is a lack of robust clinical evidence on targeted medical therapy for exercise pulmonary hypertension. Copyright ©ERS 2017.
- Find related publications in this database (using NLM MeSH Indexing)
- Advisory Committees -
- Cardiac Catheterization - adverse effects
- Cardiac Output -
- Echocardiography, Doppler -
- Europe -
- Exercise Test -
- Humans -
- Hypertension, Pulmonary - diagnosis
- Hypertension, Pulmonary - physiopathology
- Practice Guidelines as Topic -
- Societies, Medical -
- Vascular Resistance -
- Ventricular Dysfunction, Left - diagnostic imaging